AKERO THERAPEUTICS INC. - COMMON STOCK

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

13 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

08 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

21 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

30 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

09 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

28 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

09 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

11 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

08 Jun 2024 07:15:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

29 May 2024 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

10 May 2024 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

08 May 2024 06:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

30 Apr 2024 07:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

08 Mar 2024 15:02:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

07 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

05 Mar 2024 20:13:56 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

04 Mar 2024 15:21:12 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

04 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

29 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

29 Feb 2024 06:00:00 By Nasdaq GlobeNewswire